Bayer Unveils New Heart Failure & Kidney Disease Research at ACC.25
Bayer has announced the presentation of 13 new data analyses from its comprehensive KERENDIA® (finerenone) clinical trial program at the American College of Cardiology (ACC) 74th Annual Scientific Session & Expo 2025. The event, scheduled to take place in Chicago, IL, from March 29-31, 2025, will feature significant findings related to heart failure (HF) and chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
A key focus at ACC.25 will be ten presentations featuring new data from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial. This trial investigates KERENDIA’s efficacy in treating adult patients with HF with a left ventricular ejection fraction (LVEF) of ≥40%, which includes those with mildly reduced LVEF (HFmrEF) and preserved LVEF (HFpEF).
Additionally, the event will showcase findings from:
- FINE-HEART: An integrated, pooled, exploratory, participant-level analysis across three major Phase III clinical trials (FINEARTS-HF, FIDELIO-DKD, and FIGARO-DKD) evaluating finerenone’s impact across cardiovascular and renal disease.
- A post-hoc analysis of FIDELITY, a pooled analysis of FIDELIO-DKD and FIGARO-DKD, to assess long-term cardiovascular outcomes in CKD patients with T2D.
- Real-world research on patients with worsening HF within a large healthcare delivery system between 2012-2021.
Key Abstracts Presented by Bayer at ACC.25
- Efficacy and Safety of Finerenone Across the Spectrum of Kidney Risk in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
- Session: Innovations and Insights in Heart Failure With Preserved Ejection Fraction
- Abstract 904-09; March 29, 10:06am CT / 11:06am ET
- Efficacy and Safety of Finerenone by New York Heart Association Functional Class in HFmrEF/HFpEF
- Session: Innovations and Insights in Heart Failure With Preserved Ejection Fraction
- Abstract 904-11; March 29, 10:18am CT / 11:18am ET
- Finerenone, Bilirubin, and Heart Failure: An Analysis from FINEARTS-HF
- Session: Innovations and Insights in Heart Failure With Preserved Ejection Fraction
- Abstract 904-21; March 29, 11:18am CT / 12:18pm ET
- Efficacy of Finerenone According to Left Atrial Size in HFmrEF/HFpEF: Analysis from FINEARTS-HF
- Session: Finerenone: A Promising Addition to the Armamentarium?
- Abstract 920-05; March 29, 12:12pm CT / 1:12pm ET
- Finerenone in HFmrEF/HFpEF Patients with and without Atrial Fibrillation: A Prespecified Analysis of FINEARTS-HF
- Session: Finerenone: A Promising Addition to the Armamentarium?
- Abstract 920-09; March 29, 12:36pm CT / 1:36pm ET
- Finerenone, Chronic Obstructive Pulmonary Disease, and HFmrEF/HFpEF: An Analysis from FINEARTS-HF
- Session: Finerenone: A Promising Addition to the Armamentarium?
- Abstract 920-15; March 29, 1:12pm CT / 2:12pm ET
- Efficacy and Safety of Finerenone in HFmrEF/HFpEF: Anemia-Specific Analysis of FINEARTS-HF
- Session: Finerenone: A Promising Addition to the Armamentarium?
- Abstract 920-19; March 29, 1:36pm CT / 2:36pm ET
- Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: The FINEARTS-HF Trial
- Session: Finerenone: A Promising Addition to the Armamentarium?
- Abstract 920-21; March 29, 1:48pm CT / 2:48pm ET
- Temporal Biomarker and Quality of Life Changes Before Adverse Clinical Outcomes in HFmrEF/HFpEF
- Session: Heart Failure and Cardiomyopathies 04
- Abstract 1091-184; March 29, 2:00pm CT / 3:00pm ET
- Mode of Death in HFmrEF/HFpEF Patients: The FINEARTS-HF Trial
- Session: HFpEF: Hemodynamics, Treatments, and Mortality
- Abstract 949-05; March 30, 9:12am CT / 10:12am ET
- Finerenone Reduces New-Onset Atrial Fibrillation in Cardio-Kidney-Metabolic Patients: The FINE-HEART Analysis
- Session: Heart Failure and Cardiomyopathies 09
- Abstract 1194-184; March 30, 1:30pm CT / 2:30pm ET
- Worsening Heart Failure Events in Adults with Mild-to-Moderate CKD
- Session: Heart Failure and Cardiomyopathies 10
- Abstract 1215-174; March 30, 3:00pm CT / 4:00pm ET
- Mechanisms of Cardiovascular Benefit with Finerenone: Causal Mediation Analysis of BP and Albuminuria Reduction
- Session: Optimizing Cardiovascular Risk Across the Diabetes/Cardio-Kidney-Metabolic Spectrum
- Abstract 991-21; March 31, 10:48am CT / 11:48am ET
About KERENDIA® (Finerenone)
KERENDIA is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) approved by the U.S. FDA in July 2021 to reduce the risk of estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular (CV) death, non-fatal myocardial infarction (MI), and hospitalization for HF in adults with CKD associated with T2D.
Safety Information
- Contraindications: Concomitant use with strong CYP3A4 inhibitors, adrenal insufficiency.
- Warnings & Precautions: KERENDIA may cause hyperkalemia, especially in patients with CKD. Regular serum potassium monitoring is required.
- Common Adverse Reactions: Hyperkalemia (14% vs. 6.9%), hypotension (4.6% vs. 3.9%), and hyponatremia (1.3% vs. 0.7%).
- Drug Interactions: Avoid strong CYP3A4 inhibitors and inducers.
- Special Populations: Avoid in severe hepatic impairment and during breastfeeding.
Bayer remains committed to advancing research in cardiovascular and renal disease, with ACC.25 serving as a platform to share groundbreaking insights on KERENDIA and its potential impact on patients worldwide.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed approximately 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.
